Q-omics provides the consensus-scored NIPA2P4 profile across patient tissues and cancer cell-line models. NIPA2P4 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, NIPA2P4 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, NIPA2P4 RNA expression shows 6,389 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight READ, LUAD, and STAD as cancer lineages where NIPA2P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NIPA2P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NIPA2P4 survival associations across molecular data types. NIPA2P4 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NIPA2P4 RNA expression–survival associations across cancer types. High NIPA2P4 expression shows unfavorable associations in READ, THYM, SARC, ESCA, MESO and KIRP. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for NIPA2P4 RNA expression.
This table summarizes NIPA2P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for NIPA2P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NIPA2P4 shows lower tumor expression in LUAD and THCA and higher tumor expression in HNSC. The LUAD box plot shows higher NIPA2P4 RNA expression in normal versus tumor tissue (log2 FC = −0.030, t-test p = .021).
This table shows molecular features associated with NIPA2P4 in patient tissues and cancer cell lines. In patient samples, NIPA2P4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
